In other recent news, CG Oncology announced an accelerated timeline for its Phase 3 PIVOT-006 clinical trial, with topline data now expected in the first half of 2026, nearly a year ahead of schedule.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results